News Bolt Biotherapeutics, Inc.

Stocks

BOLT

US0977022039

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 07:08:42 10/07/2026 pm IST			5-day change	1st Jan Change
3.910 ^USD	-1.76%		-2.49%	-28.49%

13/05	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
13/05	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

All News

Mentions Relevance

13/05	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
13/05	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot	AQ
13/05	Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
13/05	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
18/04	Bolt Biotherapeutics : BDC-4182 AACR Poster (BBI-4182-101 TiP AACR 2026 Final)	PU
13/03	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot	AQ
13/03	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update	AQ
13/03	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/03	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
24/02	Bolt Biotherapeutics to Participate in Upcoming March Conferences	AQ
22/01	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn	RE
15/01	Bolt appoints Olta Andoni as SVP of legal and people to support platform expansion across checkout, identity, and payments	RE
13/11	Bolt Biotherapeutics Q3 collaboration revenue doubles	RE
13/11	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot	AQ
13/11	Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
13/11	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
03/25/03	Bolt Biotherapeutics, Inc. Announces Reduction of its Current Workforce by Approximately 20 Employees, or Approximately 50% of its Workforce	CI
03/25/03	Bolt Biotherapeutics, Inc. Provides Update on Ongoing Phase 1 Dose Escalation Study of BDC-4182	CI
02/25/02	Bolt Biotherapeutics to Cut Workforce by 50%; Cancer Drug Trial Data Expected in Q3 of 2026	MT
02/25/02	Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027	AQ
15/25/15	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot	AQ
15/25/15	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/25/15	Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update	AQ
07/25/07	Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025	RE
13/25/13	Bolt Biotherapeutics : Presentation (2025-05-12-BOLT BDC-3042 Event)	PU